FERAHEME demonstrated efficacy in patients with iron deficiency anemia (IDA) caused by a variety of underlying conditions3-5*
Prespecified subgroups of patients with IDA caused by underlying conditions were included in the FERAHEME clinical trials3-5*
Underlying condition subgroup | IDA TRIAL 1 FERAHEME vs placebo (N=808) | IDA TRIAL 2 FERAHEME vs Venofer® (N=605) | IDA TRIAL 3 FERAHEME vs Injectafer® (N=1997) |
---|---|---|---|
AUB | 42.6% (n=344) | 45.3% (n=274) | 24.6% (n=491) |
Cancer | 4.8% (n=39) | 7.3% (n=44) | 2.3% (n=45) |
GI disorders | 28.6% (n=231) | 33.7% (n=204) | 29.1% (n=582) |
*Primary underlying conditions of IDA, as attributed by the investigators. Patients may have had more than one underlying condition contributing to their IDA.1
FERAHEME has been extensively studied in patients with IDA and chronic kidney disease,
including those who are dialysis-dependent and non-dialysis-dependent2
Refer your patients to another physician to receive FERAHEME

The AAFP Guidelines for IDA evaluation and management recommend that patients with underlying conditions causing IDA should be treated or referred to a specialist for definitive treatment.11
AAFP=American Academy of Family Physicians; AUB=abnormal uterine bleeding; GI=gastrointestinal.